Roller E, Klumpp B, Krause J, Eichelbaum M, Schumacher K
Department of Hematology, Oncology and Immunology, Robert-Bosch-Hospital, Stuttgart, Germany.
Cancer Chemother Pharmacol. 1993;32(2):151-5. doi: 10.1007/BF00685619.
Modulators for the reversal of multidrug resistance such as R-verapamil and B8509-035, a dihydropyridine, effectively overcome multidrug resistance in vitro and are currently undergoing clinical trial. One problem with their use is the application protocol; the question as to whether they should be given by continuous administration or in sequential doses in combination with the cytotoxic drugs has to be addressed. Therefore, we examined the influence of the exposure time and the sequence of modulator administration on the active transport of the fluorescent dye rhodamine 123 (R123), a substrate for the P-glycoprotein, in the resistant lymphoblastoid cell line VCR1000 and the parental nonresistant cell line CCRF-CEM. Our results demonstrate the importance of coadministration of R-verapamil and the cytotoxic agent for the modulation of multidrug resistance, whereas the exposure sequence does not seem to be such an essential parameter in the case of B8509-035. This observation should be considered for the further design of clinical studies.
诸如R-维拉帕米和二氢吡啶类的B8509-035等多药耐药逆转调节剂在体外能有效克服多药耐药,目前正处于临床试验阶段。其使用存在的一个问题是应用方案;必须解决它们是应与细胞毒性药物联合持续给药还是分次给药的问题。因此,我们研究了暴露时间和调节剂给药顺序对荧光染料罗丹明123(R123,一种P-糖蛋白底物)在耐药淋巴母细胞系VCR1000和亲本非耐药细胞系CCRF-CEM中的主动转运的影响。我们的结果证明了R-维拉帕米与细胞毒性药物联合给药对多药耐药调节的重要性,而对于B8509-035而言,暴露顺序似乎不是一个关键参数。在进一步设计临床研究时应考虑这一观察结果。